SRT1720 HCl

For research use only.

Catalog No.S1129

142 publications

SRT1720 HCl Chemical Structure

CAS No. 1001645-58-4

SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.

Size Price Stock Quantity  
10mM (1mL in DMSO) GBP 194 In stock
GBP 139 In stock
GBP 262 In stock
GBP 794 In stock
GBP 2022 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's SRT1720 HCl has been cited by 142 publications

Purity & Quality Control

Choose Selective Sirtuin Inhibitors

Biological Activity

Description SRT1720 HCl is a selective SIRT1 activator with EC50 of 0.16 μM in a cell-free assay, but is >230-fold less potent for SIRT2 and SIRT3. SRT1720 induces autophagy.
Targets
SIRT1 [1]
(Cell-free assay)
0.16 μM(EC50)
In vitro

The maximum activation ratio of SRT1720 versus the closest sirtuin homologues, SIRT2 (EC1.5 = 37 μM) and SIRT3 (EC1.5 > 300 μM) is up to 781%. SRT1720 binds to the SIRT1 enzyme-peptide substrate complex at an allosteric site amino-terminal to the catalytic domain and lower the Michaelis constant for acetylated substrates. SRT1720 could reduce fed glucose levels. Glucose excursion during an intraperitoneal glucose tolerance test is also significantly reduced in the SRT1720 group, and comparable to rosiglitazone, a PPARγ activator that has been used to treat type 2 diabetes. SRT1720 does not have an effect on fasting glucose in chow-fed mice, revealing that pharmacological SIRT1 activation is unlikely to induce hypoglycaemia. SRT1720 significantly reduces the hyperinsulinaemia after 4 weeks, partially normalizing increased insulin levels similar to rosiglitazone treatment. SRT1720 treatment increases mitochondrial capacity by 15% in gastrocnemius muscle as measured by citrate synthase activity. [1] Higher concentrations of SRT1720 (15 μM) induces a modest (10-20%) decrease in normal cell viability. SRT1720 also significantly inhibits VEGF-dependent MM cell migration. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CACs  NFGz[XZHfW6ldHnvckBCe3OjeR?= NEPHe2o1yqEQvF2= MnrjN|DDqG2rbh?= MWHEUXNQ MkTPbY5lfWOnczDhZ5V1\SCVSWLUNUBi[3SrdnH0bY9vyqB? MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJ3NEGwOEc,OjZ{NUSxNFQ9N2F-
MC3T3-E1 NIrBTWxHfW6ldHnvckBCe3OjeR?= NVXSWW1QOTBiwsXNxsA> NF:3SYsyKGh? MYny[YR2[2W|IITo[UBVT0ZvzsKtd5RqdXWuYYTl[EBXTUeIIILlcIVie2ViaX6g[I9{\S1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5mesLi MkG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{[5O|goRjJ4MUO2PVc5RC:jPh?=
MC3T3-E1 MVvGeY5kfGmxbjDBd5NigQ>? MnHVNVAhyrWPwrC= MnfUNVIhcA>? NVnXcVB3emWmdXPld{B1cGViVlXHSkBuWk6DIHX4dJJme3Orb36gcIV3\Wy|IIP0bY12dGG2ZXSgZpkhXEeILd8y NXLvd5h2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xN|Y6PzhpPkK2NVM3QTd6PD;hQi=>
MC3T3-E1 NGPk[YhHfW6ldHnvckBCe3OjeR?= MX2yNEDPxE1? NIrRR2IyKGh? NVjPSFE1e3WycILld5NmeyC2aHWgWGdHNc7{LXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIIC0OE9xPDJiTVHQJItqdmG|ZTDvdkBUSVCNL1rOTy=> MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF|Nkm3PEc,OjZzM{[5O|g9N2F-
WE-68 MoXURZBweHSxc3nzJGF{e2G7 NIrGRo8xNTJ2IN88US=> MYmyOEBp MmrhbY5lfWOnczDj[YxtKGSnYYToJIlvKGSxc3Wg[IVx\W6mZX70cJk> MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
SK-ES-1 NXfUOHdlSXCxcITvd4l{KEG|c3H5 NGTJNVkxNTFyIN88US=> NV\xTlc4OjRiaB?= NYrtT2dlcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? NYTqUoFyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU5ODVpPkK2NFU2QDB3PD;hQi=>
SK-N-MC  NX\xOnR4SXCxcITvd4l{KEG|c3H5 NH2wcXgxNTJwNTFOwG0> MlnxNlQhcA>? NXXj[|hGcW6mdXPld{Bk\WyuIHTlZZRpKGmwIHTvd4Uh\GWyZX7k[Y51dHl? NV64SXlsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wOVU5ODVpPkK2NFU2QDB3PD;hQi=>
WE-68 MkjhSpVv[3Srb36gRZN{[Xl? NX\DfJpUOjBizszN NXL5WHF6OC1{NDDo NUTXW|gy[WO2aY\heIV{KGOjc4Dhd4UhOy95 MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
SK-ES-1 NIO5T45HfW6ldHnvckBCe3OjeR?= MVuxNEDPxE1? M2HzZlAuOjRiaB?= NFPEdnhi[3SrdnH0[ZMh[2G|cHHz[UA{Nzd? M3zEe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEW1PFA2Lz5{NkC1OVgxPTxxYU6=
SK-N-MC  NEL3VnNHfW6ldHnvckBCe3OjeR?= M3vu[lMh|ryP NF2wZ4cxNTJ2IHi= Ml3GZYN1cX[jdHXzJINie3Cjc3WgN{84 MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB3NUiwOUc,OjZyNUW4NFU9N2F-
NRK-49F MlH3SpVv[3Srb36gRZN{[Xl? M3LqeVDjiJN{wrFOwG0> NEPE[mE{PiCq MorQbY5kemWjc3XzJIV5eHKnc4Ppc44hd2ZizsGtV21CKGGwZDDmbYJzd26nY4TpckBld3OnIHTldIVv\GWwdHz5 NFfCPIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyNlAxOyd-Mk[wNlIxODN:L3G+
NRK-49F NEj2UJZHfW6ldHnvckBCe3OjeR?= M3TDbVDjiJN{wrFOwG0> M1\GdFM3KGh? NYO1c5NS\W6qYX7j[ZMheGixc4Doc5J6dGG2aX;uJI9nKEWJRmKgZY5lKFCGR1\S{tLDqA>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{MkCwN{c,OjZyMkKwNFM9N2F-
NRK-49F MYHGeY5kfGmxbjDBd5NigQ>? M3v1dFDjiJN{wrFOwG0> NGPmOoc{PiCq MofP[Y5p[W6lZYOgV3RCXDNicHjvd5Bpd3K7bHH0bY9v NUfRepF6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlIxODNpPkK2NFIzODB|PD;hQi=>
RAW264.7 NWDqSoEyTnWwY4Tpc44hSXO|YYm= M37UV|Eh|ryP MmrmOkBp NYnUN3lmfXC{ZXf1cIF1\XNidHjlJJJm\HWlZXSgV2lTXDFicILveIVqdiCxcjDtVm5CKGyndnXsd{BjgSCqaXfoJIdtfWOxc3W= M3PrTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{mzPVk2Lz5{NUe5N|k6PTxxYU6=
MCF10A MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[xWZUxNTJyIN88US=> NWe3PIluOjRiaB?= MX3y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> M4D5UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
MCF-7 NF\pbmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHu4cWwxNTJyIN88US=> NUH3bJpKOjRiaB?= NYD3XWpVemWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M{HTdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
T47D NIXJSHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7NWmgxNTJyIN88US=> M4PI[|I1KGh? M4jESJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? M2nKflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEGxN|U3Lz5{NUSxNVM2PjxxYU6=
SKBR3 NFrVS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\VNE0zOCEQvF2= MYeyOEBp MV3y[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
MDA-MB-231 NFXVPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTtdGUxNTJyIN88US=> MYKyOEBp M1XXNJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? NYrQcYNNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
SUM149 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLmNE0zOCEQvF2= MXuyOEBp MVzy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NVHpfVFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
HS578T NETCT5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqwMVIxKM7:TR?= NXnReYprOjRiaB?= Mme0doVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MmrVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
BT20 NV;DOGppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLENE0zOCEQvF2= NGrndFEzPCCq Mm\vdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTRzMUO1Okc,OjV2MUGzOVY9N2F-
A459 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj3NE0zOCEQvF2= NV7HXVE2OjRiaB?= NWrVN2t6emWmdXPld{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 MnjKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MUGzOVYoRjJ3NEGxN|U3RC:jPh?=
HCT116 NEe3S2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjNcZQ{OC1{MDFOwG0> MkP0NlQhcA>? MVvy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGSxc3Wg[IVx\W6mZX70cJk> NWm4dYRnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NVE{PTZpPkK1OFEyOzV4PD;hQi=>
Neu NU\jTJhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\jPYYxNTJyIN88US=> MlvrNlQhcA>? MlnzdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NHjpW489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
MDA-MB-231 MWfGeY5kfGmxbjDBd5NigQ>? MmTlOUDPxE1? M1jZNVghcA>? MkjqbY5kemWjc3XzJJRp\SCwdX3i[ZIhd2ZiYXPp[IlkKH[nc3njeYxieiCxcnfhcoVtdGW| NHLCZo09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
MDA-MB-231 MnzuSpVv[3Srb36gRZN{[Xl? MUC1JO69VQ>? NUfs[I53OTZiaB?= MVnpcoR2[2W|IHz5d49{d22jbDDt[Y1jemGwZTDw[ZJu\WGkaXzpfoF1cW:w NInDdpE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSxNVM2Pid-MkW0NVE{PTZ:L3G+
MC3T3-E1 M2f4RWZ2dmO2aX;uJGF{e2G7 NYTUZ2dyOTBizszN M1LRbVYxKG2rbtMg Mn\nd5VxeHKnc4Pld{B1cGViRlfGMVIue3SrbYXsZZRm\CCxc4Tlc5Bzd3SnZ3XybY4hemWuZXHz[S=> MkfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{OUCwPVUoRjJ3MkmwNFk2RC:jPh?=
MC3T3-E1 M1HKfGZ2dmO2aX;uJGF{e2G7 NUH1dopDOTBizszN MWe2NEBucW8EoB?= MUfheJRmdnWjdHXzJJRp\SCIR1[tNk1qdmS3Y3XkJI9{fGWxcILveIVo\XKrbjDtVm5CKGW6cILld5Nqd25? NUHXNVh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyPVAxQTVpPkK1NlkxODl3PD;hQi=>
MC3T3-E1 NYDOO5ZRTnWwY4Tpc44hSXO|YYm= NUHpbpZlOTBizszN MYC2NEBucW8EoB?= MVPheJRmdnWjdHXzJJRp\SCIR1[tNk1qdmS3Y3XkJI9{fGWxcILveIVo\XKrbjDtVm5CKGW6cILld5Nqd25? NIHubW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUK5NFA6PSd-MkWyPVAxQTV:L3G+
MC3T3-E1 NX\henNVTnWwY4Tpc44hSXO|YYm= NX[4bWo5OTBizszN NWLnNZVKPjBibXnuxsA> M2TsbJN2eHC{ZYPz[ZMhfGinIFLNVE01NXO2aX31cIF1\WRiVlXHSkBz\WynYYPl M2XnWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEO1OFQ1Lz5{NESzOVQ1PDxxYU6=
MC3T3-E1 MknaSpVv[3Srb36gRZN{[Xl? MV[xNEDPxE1? MYm2NEBucW8EoB?= MmS2d5VxeHKnc4Pld{B1cGViUFfGNu6yNXO2aX31cIF1\WRiT2DHJJJmdGWjc3W= NV60SnBURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzN|M{OzZpPkK0N|M{OzN4PD;hQi=>
MC3T3-E1 M1y0UWZ2dmO2aX;uJGF{e2G7 M3rBTFExKM7:TR?= M3zHUlYxKG2rbtMg M2S2cpJm\HWlZYOgeIhmKFCJRkNOtU1{fGmvdXzheIVlKHCqb4PwbI9zgWyjdHnvckBw\iCyNESvdFQzKE2DUDDrbY5ie2V? Ml[4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|M{OzN|YoRjJ2M{OzN|M3RC:jPh?=
MC3T3-E1 MmnISpVv[3Srb36gRZN{[Xl? MWCxNEDPxE1? NH;DbJQ3OCCvaX9CpC=> NYC1VJB6[XS2ZX71ZZRmeyC2aHWgVGdHOs7zLXnu[JVk\WRicHjvd5Bpd3K7bHH0bY9vKG:oIHLveIghVUWNMT:yJIFv\CCUYX[tNS=> Ml7OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|M{OzN|YoRjJ2M{OzN|M3RC:jPh?=
RPE Moe4R4VtdCCYaXHibYxqfHliQYPzZZk> MoPwOUDDvU1? MmTUNUBp Ml\ZZZR1\W63YYTld{BQSc7{LXnu[JVk\WRiZHXjdoVie2Vib3[gZ4VtdCC4aXHibYxqfHl? MkH4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyM{[5N|goRjJ2MEO2PVM5RC:jPh?=
9607 NGjrdnJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVX6UYNsOSEQvF2= M{HFeFM3KGh? NX:3dGRzcW6lcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClb33wZZJm\CC5aYToJI1mdGG2b37pckBidG:wZR?= M1rvN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{K2PVQ6Lz5{M{eyOlk1QTxxYU6=
9607 M1jKOWZ2dmO2aX;uJGF{e2G7 MYCxJO69VQ>? NXXORVlKOzZiaB?= MXvpcoNz\WG|ZYOgV2lTXDFiYX7kJIRm[3KnYYPl[EBi[2W2eXzheIVlNXB3MzDlfJBz\XO|aX;u MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd{Nkm0PUc,OjN5Mk[5OFk9N2F-
RPMI.8226 NH\HdpRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3HvfVcwOTBizszN NEPoWo0zPCCq MYrk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
U266 MnvKR4VtdCCYaXHibYxqfHliQYPzZZk> NFraboM4NzFyIN88US=> M4rsWlI1KGh? MU\k[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl3MEeyPEc,OjF7NUC3Nlg9N2F-
MM.1S NEL6O5FE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NECx[GY4NzFyIN88US=> MlLqNlQhcA>? NGPoV5dl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> M4q0dlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
KMS12 MlvTR4VtdCCYaXHibYxqfHliQYPzZZk> NH3Ed3U4NzFyIN88US=> M{\BSFI1KGh? NG\UcXRl\WO{ZXHz[ZMhfmmjYnnsbZR6KGOxbnPlcpRz[XSrb36g[IVx\W6mZX70cJk> MnTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
LR5 NWjlRWd3S2WubDDWbYFjcWyrdImgRZN{[Xl? MWO3M|ExKM7:TR?= MW[yOEBp NYfDd5px\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 M{jafFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
MM.1R MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NY\NbphEPy9zMDFOwG0> NX7q[3VOOjRiaB?= MYjk[YNz\WG|ZYOgeoli[mmuaYT5JINwdmOnboTyZZRqd25iZHXw[Y5l\W62bIm= M2W0RlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
Ina6 M1PKVWNmdGxiVnnhZoltcXS7IFHzd4F6 NETzeIs4NzFyIN88US=> MmG0NlQhcA>? NWrscWFQ\GWlcnXhd4V{KH[rYXLpcIl1gSClb37j[Y51emG2aX;uJIRmeGWwZHXueIx6 M3jx[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUWwO|I5Lz5{MUm1NFczQDxxYU6=
RPMI-8226 NG\sO|dCeG:ydH;zbZMhSXO|YYm= M{jVPVcwOTBizszN NInkSXUzPCCq M1XaZYlv\HWlZYOgZUB{cWewaX\pZ4FvfCCrbnPy[YF{\SCrbjD0bIUhSW6wZYjpckBXMy:SSfMIluKh[XCxcITvd4l{ MnTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7NUC3NlgoRjJzOUWwO|I5RC:jPh?=
MM.1R  MkP0RZBweHSxc3nzJGF{e2G7 NWnweYl7Py9zMDFOwG0> M3nQNlI1KGh? MmjqbY5lfWOnczDhJJNq\26rZnnjZY51KGmwY4LlZZNmKGmwIITo[UBCdm6neHnuJHYsN1CL4pkSxsBieG:ydH;zbZM> NWjiZ4dbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OVA4OjhpPkKxPVUxPzJ6PD;hQi=>
H411EC3 MYPGeY5kfGmxbjDBd5NigQ>? M4\MfFUxNzFyMDDuUS=> MkH1OkBp MXrpcoNz\WG|ZYOgV2lTXDFiYXP0bZZqfHliaX6geIhmKHC{ZYPlcoNmKG:oIGTTRUwhWEWSQ1ugZYN1cX[rdImsJI1TVkFibHX2[Yx{KG:oIGDjb|Eh[W6mIGDnZ|HPuSxiYX7kJIVt\X[jdHnu[{BodHWlb4PlJJBzd2S3Y4Tpc44> NUDjOoN4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVIxQTZpPkKxNlEzODl4PD;hQi=>
hepatocytes Mn3GSpVv[3Srb36gRZN{[Xl? NEjVZmkyOCCwTR?= NWn1SY9OPiCq NYLZOmZScW6lcnXhd4V{KFOLUmSxJIFkfGm4aYT5JIlvKHSqZTDwdoV{\W6lZTDv[kBVW0FuIGDFVGNMKGGldHn2bZR6NCCvUl7BJIxmfmWuczDv[kBR[2tzIHHu[EBR\2NzzsGsJIFv\CCnbHX2ZZRqdmdiZ3z1Z49{\SCycn;keYN1cW:w NXXGbHhTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGyNVIxQTZpPkKxNlEzODl4PD;hQi=>
hepatocytes NVHKOJN5TnWwY4Tpc44hSXO|YYm= NH7DNYcyOCCwTR?= NWK2SVg6PiCq MWfpcoNz\WG|ZYOgTI1o[3MEoHHu[OKhSWOlwrDn[Y5mKGW6cILld5Nqd25? M{P3b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMkGyNFk3Lz5{MUKxNlA6PjxxYU6=
U2OS MoHiSpVv[3Srb36gZZN{[Xl? NHLtNFQxNjFyIIXN M2\UNWFkfGm4YYTpc44hd2ZiU1nSWFEhcW5iaIXtZY4hXTKRUzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBxPTNiZHXhZ4V1gWyjdHnvckBt\X[nbDDheEAxNjFyIIXN M1vNb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6MES2OFA6Lz5zOEC0OlQxQTxxYU6=
A673 MUnxTHRUKGG|c3H5 NHi3[GJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NEXCU4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
DAOY MlzCdWhVWyCjc4PhfS=> MmrHdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 MmfidWhVWyCjc4PhfS=> NH7scXpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD M3rWc5FJXFNiYYPzZZk> M1;ibJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
MG 63 (6-TG R) MYPxTHRUKGG|c3H5 MmDndWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NGHDeII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NH\0UnhyUFSVIHHzd4F6 NXnXb|hIeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> NGTVWFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 NUTZSYhZeUiWUzDhd5NigQ>? NIPwOGtyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz NIDVXpo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NEn6dGJyUFSVIHHzd4F6 M1PkNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy| MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 NWfJWFgyeUiWUzDhd5NigQ>? NGTyWWZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUnizNEBk\Wyucx?= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 M{KzO5FJXFNiYYPzZZk> MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN? MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh18 NIq5c29yUFSVIHHzd4F6 MWLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>? NVHxNG1zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Cleaved-PARP-1 / Cleaved-caspase-3 / LC3-II / p62 / SIRT1; 

PubMed: 26655844     


SU86.86 cells were transfected with control siRNA, SIRT1 siRNA#1, or DBC1 siRNA. 24 hours after transfection, cells were re-plated and allowed to attach for 24 hours. Cells were then treated with vehicle (control) or 5 μM SRT1720 for 16 hours. Expression 䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෕Ð鑸᎒彿堙奋堙巫堙

26655844
Immunofluorescence
Cathepsin B; 

PubMed: 26655844     


SU86.86 cells were incubated with vehicle or 5 μM SRT1720 for 5 hours for LysoTracker Red labeling and 16 hours for cathepsin B immunofluorescence, followed by DAPI staining.

26655844
Growth inhibition assay
Cell viability ; 

PubMed: 25411356     


MTT viability assay of cancer cell lines treated with different doses of SRT1720 for 24 hours. 

25411356
In vivo In DIO mice SRT1720 mimics several of the effects observed after calorie restriction including improved insulin sensitivity, normalized glucose and insulin levels, and increased mitochondrial capacity. In addition, in diet-induced obese and genetically obese mice, SRT1720 improves insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity. Thus, SRT1720 is a promising new therapeutic agent for treating diseases of ageing such as type 2 diabetes. Consistent with improved glucose tolerance, the glucose infusion rate required to maintain euglycaemia is approximately 35% higher in SRT1720-treated fa/fa rats, and the total glucose disposal rate is increased by approximately 20%. [1] SRT1720 also prevents multiple myeloma tumor growth. SRT1720 increases the cytotoxic activity of bortezomib or dexamethasone. [2]

Protocol

Kinase Assay:[1]
- Collapse

SIRT1 fluorescence polarization assay:

In the SIRT1 FP assay, SIRT1 activity is monitored using a 20 amino acid peptide (Ac-Glu-Glu-Lys(biotin)-Gly-Gln-Ser-Thr-Ser-Ser-His-Ser-Lys(Ac)-Nle-Ser-Thr-Glu-Gly–Lys(MR121 or Tamra)-Glu-Glu-NH2) derived from the sequence of p53. The peptide is N-terminally linked to biotin and C-terminally modified with a fluorescent tag. The reaction for monitoring enzyme activity is a coupled enzyme assay where the first reaction is the deacetylation reaction catalyzed by SIRT1 and the second reaction is cleavage by trypsin at the newly exposed lysine residue. The reaction is stopped and streptavidin is added in order to accentuate the mass differences between substrate and product. The sensitivity of the FP assay allows identification of SRT1720. The fluorescence polarization reaction conditions are as follows: 0.5 μM peptide substrate, 150 μM βNAD+, 0-10 nM SIRT1, 25 mM Tris-acetate pH 8, 137 mM Na-Ac, 2.7 mM K-Ac, 1 mM Mg-Ac, 0.05% Tween-20, 0.1% Pluronic F127, 10 mM CaCl 2, 5 mM DTT, 0.025% BSA, and 0.15 mM nicotinamide. The reaction is incubated at 37 °C and stopped by addition of nicotinamide, and trypsin is added to cleave the deacetylated substrate. This reaction is incubated at 37 °C in the presence of 1 μM streptavidin. Fluorescent polarization is determined at excitation (650 nm) and emission (680 nm) wavelengths.
Cell Research:[2]
- Collapse
  • Cell lines: Human vascular endothelial cells (HUVECs)
  • Concentrations: 5 μM
  • Incubation Time: 2 hours
  • Method: Transwell Insert Assays are utilized to measure migration. In vitro angiogenesis is assessed by Matrigel capillary-like tube structure formation assay. For endothelial tube formation assay, human vascular endothelial cells (HUVECs) are obtained from Clonetics and maintained in endothelial cell growth medium-2 containing 5% FBS. After three passages, HUVEC cell viability is measured with the trypan blue exclusion assay, and <5% of cell death is observed with SRT1720 treatment.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Chase-SCID mice with MM.1S cells
  • Dosages: 200 mg/kg
  • Administration: Orally
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 38 mg/mL (75.09 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 506.02
Formula

C25H23N7OS.HCl

CAS No. 1001645-58-4
Storage powder
in solvent
Synonyms N/A
Smiles C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can we prepare Srt1720 for in vivo mouse studies?

  • Answer:

    SRT1720 HCl can be dissolved in 30% PEG 400+0.5% Tween 80+5% Propylene glycol at 30mg/ml as a suspension. It is fine for oral gavage. And we’ve also found that it can be dissolved in 2% DMSO+30% PEG 300+1%Tween 80+ddH2O at 3mg/ml clearly, which could be used for injection. When prepare the solution, please dissolve the compound in DMSO clearly first, then add PEG and Tween. After they mixed well, dilute with water.

Sirtuin Signaling Pathway Map

Related Sirtuin Products

Tags: buy SRT1720 HCl | SRT1720 HCl supplier | purchase SRT1720 HCl | SRT1720 HCl cost | SRT1720 HCl manufacturer | order SRT1720 HCl | SRT1720 HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID